Halcion (Triazolam)

Halcion (triazolam) is indicated for short‑term management of certain sleep and anxiety disorders.

• Short‑term treatment of insomnia, particularly difficulty falling asleep.
• Management of transient anxiety episodes, such as pre‑procedural nervousness.
• Use as a hypnotic adjunct in patients requiring rapid onset of sleep.
• May be prescribed for adjustment of sleep patterns in shift‑work or jet‑lag situations under medical supervision.
• Short courses (typically ≤2 weeks) to minimize dependence risk.
• Occasionally employed in diagnostic sleep studies to facilitate patient compliance.

The side‑effect profile of triazolam reflects its benzodiazepine class and varies with dose and duration.

Common

• Drowsiness or fatigue.
• Dizziness or light‑headedness.
• Impaired coordination or balance.
• Memory disturbances, especially anterograde amnesia.
• Headache.
• Gastrointestinal discomfort such as nausea.
• Visual disturbances or blurred vision.
• Dry mouth.

Serious

• Respiratory depression, particularly when combined with other depressants.
• Severe allergic reactions (rash, swelling, difficulty breathing).
• Paradoxical reactions like agitation, aggression, or hallucinations.
• Dependence, withdrawal symptoms, or rebound insomnia after abrupt discontinuation.
• Mood changes including depression or suicidal thoughts.
• Seizures.

When prescribing triazolam, clinicians consider several safety precautions to reduce the risk of adverse outcomes.

• Limit use to the shortest effective period, generally no longer than two weeks.
• Assess patient history for substance abuse, dependence, or previous benzodiazepine reactions.
• Use caution in individuals with respiratory disorders such as COPD or sleep apnea.
• Avoid prescribing to pregnant or breastfeeding women unless benefits clearly outweigh risks.
• Monitor elderly patients closely due to increased sensitivity and fall risk.
• Evaluate liver or kidney impairment, as it may affect drug clearance.

Triazolam can interact with other medications, altering its sedative effect or increasing toxicity.

Avoid

• Other central nervous system depressants (e.g., alcohol, opioids, barbiturates).
• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir.
• Antidepressants that lower seizure threshold (e.g., bupropion).

Use with caution

• Sedating antihistamines or other antihistamines.
• Certain antiepileptic drugs (e.g., carbamazepine, phenytoin) that may reduce triazolam levels.
• Oral contraceptives, which can increase triazolam concentrations.